Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Hepatology
•
Hepatology
What is your clinical approach to the evaluation of cytopenias in patients with end-stage liver disease?
Related Questions
If you do not have easy access to shear wave elastography (aka Fibroscan), what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk-stratify them?
What is your approach to a patient with "low" liver enzymes?
Do you always consider ADPCKD or ARPCKD in a patient who is incidentally found to have liver and renal cysts?
When would you consider use of EUS guided liver biopsy over percutaneous and/or transjugular?
How do you approach a patient who has incidentally found liver and renal cysts?
Do you avoid peritoneal dialysis in cirrhotic patients with ascites?
How do you determine whether to limit volume removal during therapeutic paracentesis in a patient without acute or chronic kidney disease?
What is your approach to a patient with an elevated alkaline phosphatase level, but negative PBC serologies and normal biliary imaging?
Do you obtain liver biopsy to confirm the diagnosis of cirrhosis if cirrhotic liver morphology is noted on imaging?
How do you approach the use of viscoelastic assays (ex: TEG, ROTEM) in patients with identified coagulopathy in the peri-procedural period?
